Oaktree Acquisition Corp III Life Sciences Unit
OACCU
5 hedge funds and large institutions have $9.24M invested in Oaktree Acquisition Corp III Life Sciences Unit in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
2% more capital invested
Capital invested by funds: $9.07M → $9.24M (+$174K)
0.25% less ownership
Funds ownership: 4.95% → 4.7% (-0.25%)
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DAM
DLD Asset Management
New York
|
-$33.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.29K |
| 3 |
CS
Clear Street
New York
|
-$2.69K |
OACCU Hedge Fund Activity: Q2 2026 in Review
5 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Oaktree Acquisition Corp III Life Sciences Unit (OACCU) for Q2 2026, worth a combined $9.24M — up 1.9% from $9.07M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of OACCU and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was DLD Asset Management, exiting entirely with an estimated $33.4K sold.
- 5 institutional investors held Oaktree Acquisition Corp III Life Sciences Unit (OACCU) as of Q2 2026, down from 6 in Q1 2026.
- Funds reported $9.24M of Oaktree Acquisition Corp III Life Sciences Unit stock for Q2 2026, up 1.9% quarter-over-quarter.
- 0 funds opened new Oaktree Acquisition Corp III Life Sciences Unit positions in Q2 2026 and 1 closed out, a net change of -1 holder.
- The largest Oaktree Acquisition Corp III Life Sciences Unit seller in Q2 2026 was DLD Asset Management, an estimated $33.4K sold.
Based on aggregated 13F filings for Q2 2026.